Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Review Article

A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2

Author(s): Nikita Khanna, Sandip V. Pawar* and Anil Kumar

Volume 13, Issue 3, 2021

Published on: 14 March, 2021

Page: [203 - 221] Pages: 19

DOI: 10.2174/2589977513666210315094752

Price: $65

Abstract

Background: The novel coronavirus disease 2019 (COVID-19), emerged in Wuhan, China in December 2019 and then spread worldwide rapidly. The records from World Health Organisation (WHO), Centres of Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) backup the fact that no medications have proven to be completely effective for prevention or treatment of SARS-CoV-2. The clinical trials are underway for many repurposed, investigational drugs and vaccine candidates. BioNTech and Pfizer Inc, Moderna, Gamaleya institute and University of Oxford (collaboration with AstraZeneca) announced positive results in the Phase 3 interim analyses of vaccine trials in November 2020. Twelve countries have approved Pfizer- BioNTech COVID-19 vaccine for emergency use, as of December 2020.

Objective: The objective was to summarize the repurposed/investigational drugs, their mechanism of action, and rationale for their use in COVID-19 treatment. The article also aimed to summarize the vaccine trials that are currently undergoing across the globe.

Methods: In order to find the content for review, studies defining COVID-19 chronology, repurposed drugs along with their mode of action and potential vaccine trials were studied and summarized.

Results and Conclusion: The article summarizes potential therapeutic candidates (repurposed and investigational agents) for SARS-CoV-2, their possible mechanism of action and discussion related to their involvement in recent clinical trials. Innovative vaccine platform technologies are also highlighted that are recently being used in the vaccine production pipeline.

Keywords: COVID-19, drug repurposing, novel coronavirus, vaccine, antivirals, SARS CoV-2.

Graphical Abstract
[1]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 323(18): 1824-36.
[PMID: 32282022]
[2]
Seyran M, Pizzol D, Adadi P, et al. Questions concerning the proximal origin of SARS-CoV-2. J Med Virol 2021; 93(3): 1204-6.
[http://dx.doi.org/10.1002/jmv.26478]
[3]
Dashraath P, Wong JLJ, Lim MXK, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020; 222(6): 521-31.
[http://dx.doi.org/10.1016/j.ajog.2020.03.021] [PMID: 32217113]
[4]
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433.
[http://dx.doi.org/10.1016/j.jaut.2020.102433] [PMID: 32113704]
[5]
Lobo-Galo N, Terrazas-López M, Martínez-Martínez A, Díaz-Sánchez ÁG. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. J Biomol Struct Dyn 2021; 39(9): 3419-27.
[http://dx.doi.org/10.1080/07391102.2020.1764393] [PMID: 32364011]
[6]
Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020; 133(9): 1015-24.
[http://dx.doi.org/10.1097/CM9.0000000000000722] [PMID: 32004165]
[7]
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020; 14(1): 69-71.
[http://dx.doi.org/10.5582/bst.2020.01020] [PMID: 31996494]
[8]
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. In: J Med Virol. 2020; 92: pp. (4)441-7.
[http://dx.doi.org/10.1002/jmv.25689]
[9]
Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Eur J Clin Invest 2020; 50(3): e13209.
[http://dx.doi.org/10.1111/eci.13209]
[10]
Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18(1): 41-58.
[http://dx.doi.org/10.1038/nrd.2018.168] [PMID: 30310233]
[11]
Aljabali AAA, Bakshi HA, Satija S, et al. COVID-19: underpinning research for detection, therapeutics, and vaccines development. Pharm Nanotechnol 2020; 8(4): 323-53.
[http://dx.doi.org/10.2174/2211738508999200817163335] [PMID: 32811406]
[12]
Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: what’s next? Br J Pharmacol 2020; 177(21): 4813-24.
[http://dx.doi.org/10.1111/bph.15072] [PMID: 32329520]
[13]
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14(1): 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[14]
Smith T, B. J, LeClaire A, Prosser T. COVID-19 Drug Therapy. Clinical Drug Information. In: 2020. Available from: https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_2020-8-28.pdf
[15]
Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[16]
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized Dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[17]
Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.03.22.20040758.
[18]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1): 105949.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[19]
WHO Director-General's opening remarks at the media briefing on COVID-19. 2020 May; 25. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the- media-briefing-on-covid-19- 25-may-2020
[20]
National Institute of Health [NIH]. Search clinical trials related to COVID-19. Available from: https://www.nih.gov
[21]
Lyngbakken MN, Berdal J-E, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun 2020; 11(1): 5284.
[http://dx.doi.org/10.1038/s41467-020-19056-6] [PMID: 33082342]
[22]
Chu CM, Cheng VCC, Hung IFN, et al. HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59(3): 252-6.
[http://dx.doi.org/10.1136/thorax.2003.012658] [PMID: 14985565]
[23]
Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[24]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[25]
No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19patients studied in RECOVERY. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir. University of Oxford 2020; 2.
[26]
Bagheri M, Niavarani A. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. J Biomol Struct Dyn 2020. [Online ahead of print]
[http://dx.doi.org/10.1080/07391102.2020.1830854] [PMID: 33030105]
[27]
Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect 2020; 26(7): 917-21.
[http://dx.doi.org/10.1016/j.cmi.2020.04.026]
[28]
Gao W, Chen S, Wang K, et al. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series. Virol J 2020; 17(1): 162.
[http://dx.doi.org/10.1186/s12985-020-01428-5] [PMID: 33097047]
[29]
International clinical trials assessing vitamin D in people with COVID-19. ClinicalTrialsgov. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=vitamin+D&cntry=&state=&city=&dist=
[30]
Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol 2020; 8(9): 735-6.
[http://dx.doi.org/10.1016/S2213-8587(20)30268-0] [PMID: 32758429]
[31]
Rhodes JM, Subramanian S, Laird E, Kenny RA. Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Aliment Pharmacol Ther 2020; 51(12): 1434-7.
[http://dx.doi.org/10.1111/apt.15777] [PMID: 32311755]
[32]
Pereira M, Dantas Damascena A, Galvão Azevedo LM, de Almeida Oliveira T, da Mota Santana J. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. Crit Rev Food Sci Nutr 2020; 1-9.
[http://dx.doi.org/10.1080/10408398.2020.1841090] [PMID: 33146028]
[34]
Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018; 9(2): e00221-18.
[http://dx.doi.org/10.1128/mBio.00221-18] [PMID: 29511076]
[35]
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20(4): 398-400.
[http://dx.doi.org/10.1016/S1473-3099(20)30141-9] [PMID: 32113510]
[36]
Zhang T, He Y, Xu W, Ma A, Yang Y, Xu KF. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): a rapid response to urgent need. Sci China Life Sci 2020; 63(5): 774-6.
[http://dx.doi.org/10.1007/s11427-020-1660-2] [PMID: 32124179]
[37]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[38]
National Institute of Allergy and Infectious Diseases 2020.
[39]
Adaptive COVID-19 Treatment Trial 2 (ACTT-2). NCT04401579 Available from: https://clinicaltrials.gov/ct2/show/NCT04401579
[40]
U.S. Food and Drug Administration. [cited 2020 Dec 19]. Available from: https://www.fda.gov/
[41]
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health Available at https://www.covid19treatmentguidelines.nih.gov/ 2021
[42]
Adaptive COVID-19 Treatment Trial 3 (ACTT-3). NCT04492475 https://clinicaltrials.gov/ct2/show/NCT04492475
[43]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[44]
Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Beijing, China: Engineering 2020.
[45]
Russian Direct Investment Fund. FL: Russian Direct Investment Fund. Inc.; c2013-2021 [cited 2020 Dec 19]. Available from: https://rdif.ru/Eng_About/
[46]
The Independent. [cited 2020 Dec 19]. Available from: https://www.independent.co.uk/
[47]
Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv 2020. 2020.2001.2031.929042.
[48]
Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. J Virol 2016; 90(19): 8924-33.
[http://dx.doi.org/10.1128/JVI.01429-16] [PMID: 27466418]
[49]
Pindiprolu SKSS, Pindiprolu SH. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Med Hypotheses 2020; 140: 109765-5.
[http://dx.doi.org/10.1016/j.mehy.2020.109765] [PMID: 32361588]
[50]
Jean S-S, Hsueh P-R. Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther 2020; 18(9): 843-7.
[http://dx.doi.org/10.1080/14787210.2020.1771181] [PMID: 32419524]
[51]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[52]
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395(10223): 473-5.
[http://dx.doi.org/10.1016/S0140-6736(20)30317-2] [PMID: 32043983]
[53]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[54]
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020; 371: m3939.
[http://dx.doi.org/10.1136/bmj.m3939] [PMID: 33093056]
[55]
COVID-19 clinical trials https://clinicaltrials.gov
[56]
Ianevski A, Yao R, Fenstad MH, et al. Potential Antiviral Options against SARS-CoV-2 Infection. Viruses 2020; 12(6): 642.
[http://dx.doi.org/10.3390/v12060642] [PMID: 32545799]
[57]
Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D. The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics 2021; 11(4): 1690-702.
[http://dx.doi.org/10.7150/thno.53691] [PMID: 33408775]
[58]
Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science 2020; 368(6494): 948-50.
[http://dx.doi.org/10.1126/science.abc5312] [PMID: 32393526]
[59]
Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(10): 667-8.
[http://dx.doi.org/10.1038/d41573-020-00151-8] [PMID: 32887942]
[60]
Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(5): 305-6.
[http://dx.doi.org/10.1038/d41573-020-00073-5] [PMID: 32273591]
[61]
COVID-19 vaccine development pipeline- Tracker by Vaccine Centre, London School of Hygiene and Tropical Medicine. Available from: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/
[62]
COVID19 Vaccine Tracker. FL: McGill COVID19 Vaccine Tracker Team; c2021 [cited 2020 Dec 19]. Available from: https://covid19.trackvaccines.org/
[64]
Regulatory Decision Summary - Pfizer-BioNTech COVID-19 Vaccine. Health Canada, Government of Canada https://covid- vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00730
[65]
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults. NCT04368728 ClinicalTrialsgov (Registry) Available from: https://clinicaltrials.gov/ct2/show/NCT04368728
[66]
A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults. EudraCT 2020-001038-36 EU Clinical Trials Register (Registry) European Union
[67]
Investigating a Vaccine Against COVID-19. NCT04400838 ClinicalTrialsgov (Registry) Available from: https://clinicaltrials.gov/ct2/show/NCT04400838
[68]
A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19. EudraCT 2020-001228-32 EU Clinical Trials Register (Registry)
[69]
A phase III study to investigate a vaccine against COVID-19. ISRCTN89951424
[http://dx.doi.org/10.1186/ISRCTN89951424]
[70]
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19. Available from: https://clinicaltrials.gov/show/NCT04530396
[71]
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. Available from: https://clinicaltrials.gov/show/NCT04470427
[72]
Palca J. COVID-19 vaccine candidate heads to widespread testing in U.S. Available from: https://www.ncbi.nlm.nih.gov/search/research-news/11431/
[73]
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE). NCT04505722 Available from: https://clinicaltrials.gov/ct2/show/NCT04505722
[74]
A Study of Ad26.COV2.S in Adults (COVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04436276
[75]
Sadoff J, Le Gars M, Shukarev G, et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv 2020.09.23.20199604.
[76]
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults. NCT04449276 Available from: https://clinicaltrials.gov/ct2/show/NCT04449276
[77]
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers. NCT04336410 Available from: https://clinicaltrials.gov/ct2/show/NCT04336410 [10 December 2020].
[78]
IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO’s COVID-19 DNA vaccine in South Korea. International Vaccine Institute https://www.ivi.int/ivi-inovio-and-knih-to-partner-with-cepi-in-a-phase-i-ii-clinical- trial-of-inovios-covid-19-dna-vaccine-in-south-korea/
[79]
Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona). NCT04527575 Available from: https://clinicaltrials.gov/ct2/show/NCT04527575
[80]
Study of COVID-19 DNA Vaccine (AG0301-COVID19). NCT04463472 Available from: https://clinicaltrials.gov/ct2/show/NCT04463472
[81]
AnGes, Inc. Archived from the original on 10 December 2020.https://www.anges.co.jp/en/index.php
[82]
CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 STARR™ mRNA Vaccine Candidate LUNAR-COV19 (ARCT-021) in a Phase 1/2 study https://www.bioindustry.org/news-listing/cti-and-arcturus-therapeutics-announce-initiation-of-dosing-of-covid-19-starr-mrna-vaccine-candidate-lunar- cov19-arct-021-in-a-phase-12-study.html
[83]
Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT04480957
[84]
Safety and Immunity of Covid-19 aAPC Vaccine. NCT04299724. Available from: https://clinicaltrials.gov/ct2/show/NCT04299724
[85]
Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. NCT04276896. Available from: https://clinicaltrials.gov/ct2/show/NCT04276896
[86]
Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women. ISRCTN17072692.,
[http://dx.doi.org/10.1186/ISRCTN17072692]
[87]
Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults. NCT04445389. Available from: https://clinicaltrials.gov/ct2/show/NCT04445389
[88]
S.Korea's Genexine begins human trial of coronavirus vaccine. Available from: https://www.reuters.com/article/health-coronavirus-genexine- vaccine-idUSL4N2DW1T3
[89]
A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above . ChiCTR2000034112. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=55524
[90]
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19. NCT04540419. Available from: https://clinicaltrials.gov/ct2/show/NCT04540419
[91]
A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells). ChiCTR2000034780. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=56651
[92]
Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19). NCT04383574. Available from: https://clinicaltrials.gov/ct2/show/NCT04383574
[93]
Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV). NCT04456595. Available from: https://clinicaltrials.gov/ct2/show/NCT04456595
[94]
A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia. INA-WXFM0YX. Available from: https://www.ina-registry.org/index.php?act=registry_trial_detail&code_trial=16202009080721WXFM0YX
[95]
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant. Available from: https://clinicaltrials.gov/ct2/show/NCT04368988
[96]
An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers. NCT04641481. Available from: https://clinicaltrials.gov/ct2/show/NCT04641481
[97]
GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine http://www.pmlive.com/pharma_news/gsk,_medicago_launch_phase_23_clinical_trials_of_plant-derived_covid-19_vaccine_1356854
[98]
Clinical Study of Recombinant Novel Coronavirus Vaccine. NCT04466085. Available from: https://clinicaltrials.gov/ct2/show/NCT04466085
[99]
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19. NCT04412538 Available from: https://clinicaltrials.gov/ct2/show/NCT04412538
[100]
SCB-2019 as COVID-19 Vaccine. NCT04405908. Available from: https://clinicaltrials.gov/ct2/show/NCT04405908
[101]
Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial. Available from: https://www.clinicaltrialsarena.com/news/clover-vaccine- covid-19-trial/
[102]
Monovalent Recombinant COVID19 Vaccine (COVAX19). NCT04453852 Available from: https://clinicaltrials.gov/ct2/show/NCT04453852
[103]
A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults. NCT04495933. Available from: https://clinicaltrials.gov/ct2/show/NCT04495933
[104]
COVID-19 vaccine tracker. Regulatory Affairs Professional Society (RAPS). FL: Regulatory Affairs Professional Society; c2021 [cited 2020 Dec 19]. Available from: https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy